neuroClues, a leading medtech startup, has secured €5 million in its latest funding initiative. This development aims to enhance their innovative eye-tracking technology.
Eye movements reveal underlying neurological disorders, and neuroClues is harnessing this potential with cutting-edge solutions. Their recent funding will accelerate market expansion and regulatory approvals.
neuroClues has achieved a significant milestone by closing a €5 million pre-Series A funding round. The investment was led by White Fund and the European Commission’s EIC Accelerator, with contributions from Invest.BW and notable business angels.
These funds increase the company’s total to €12 million, supporting expansion within European and North American markets. Plans include applying for FDA approval in the U.S. (2024) and securing CE marking in Europe (2025).
Founded by Antoine Pouppez and Pierre Daye, neuroClues pioneers a medical device that uses eye-tracking to diagnose neurological diseases.
The device, designed as a headset, records up to 800 infrared images per eye per second. It offers an intuitive interface that aids in detecting diseases such as Parkinson’s and Alzheimer’s years before symptoms emerge.
This portable technology equips clinics and researchers with objective and non-invasive biomarkers critical for early diagnosis and patient care.
Current misdiagnosis of conditions like Parkinson’s, where a quarter of patients are inaccurately diagnosed, underscores the need for neuroClues’ innovation.
The prolonged average diagnostic period results in a loss of dopamine-producing neurons, crucial for patient health. neuroClues’ device promises earlier detection, potentially altering treatment pathways.
The company envisions creating a ‘stethoscope for the brain’, revolutionising how neurological disorders are identified and managed.
Antoine Pouppez, the CEO, expresses confidence in transforming diagnostic and management landscapes of neurodegenerative diseases.
Clinical studies with the Brain Institute highlight early detection capabilities, potentially reducing confirmatory diagnostic time from about a year to mere months.
The technology identifies eye movement alterations, offering early warnings for brain dysfunctions, enabling preemptive interventions such as therapy and lifestyle adjustments.
In partnership with esteemed neurologists like Professor Marie Vidailhet, neuroClues’ research advances treatment options.
Professor Vidailhet remarks on the opportunity for patients to engage in self-therapies, enhancing personal health management before severe symptoms arise.
Such collaborations amplify neuroClues’ technology’s credibility and potential impact on healthcare systems globally.
The recent funding supports strategic market expansion, targeting Europe and North America.
neuroClues plans to leverage this financial backing to enhance regulatory approvals and broaden product availability.
By focusing on these key markets, neuroClues aims to establish a solid presence in the medtech industry.
neuroClues’ innovation signifies a leap forward in medical technology, providing critical tools for early disease detection and management.
neuroClues is poised to reshape neurological diagnostics with its pioneering technology. Their efforts promise advanced healthcare solutions and improved patient outcomes.
